Testosterone Should Be Held Before Total Knee Replacement
Based on recent high-quality evidence, testosterone injections should be discontinued in the perioperative period before total knee replacement due to significantly increased risks of reoperation and infection.
Key Evidence Supporting Discontinuation
The most recent and highest quality study 1 demonstrates that male patients prescribed testosterone replacement therapy (TRT) within one year prior to primary TKA face substantially elevated risks:
- Significantly higher cumulative incidence of reoperation for infection at 1,2,3,4, and 5 years postoperatively (all p<0.05)
- Significantly higher all-cause reoperation rates at all time points through 5 years
- This held true even after matching for demographics, comorbidities (diabetes, hypertension, obesity, smoking), and other confounding factors
Additional supporting evidence 2 shows that intramuscular testosterone formulations carry particularly high risk, with 18.5% revision rate in IM users versus 3% in topical users (p=0.046). Of the six revisions identified, five occurred in the IM testosterone group.
Clinical Reasoning
Why Testosterone Increases Surgical Risk
While the Endocrine Society guidelines 3, 4 provide comprehensive monitoring protocols for testosterone therapy, they do not address perioperative surgical risk. The guidelines focus on:
- Hematocrit monitoring (stop if >54%)
- PSA surveillance
- Cardiovascular monitoring
However, these monitoring parameters don't capture the infection and reoperation risks specific to orthopedic surgery.
Mechanism of Increased Risk
The elevated infection risk likely relates to:
- Immunomodulatory effects of supraphysiological testosterone levels
- Increased hematocrit (testosterone raises hemoglobin dose-dependently 3, 4), potentially affecting tissue perfusion
- Higher serum testosterone levels with IM formulations (652.6 ng/dL vs 356.1 ng/dL for topical 2)
Practical Recommendations
Timing of Discontinuation
- Hold testosterone at least 4-6 weeks before surgery to allow:
- Normalization of hematocrit (testosterone enanthate/cypionate half-life is approximately 8 days)
- Reduction of immunomodulatory effects
- Clearance of supraphysiological levels
Formulation-Specific Considerations
- IM testosterone (enanthate/cypionate): Requires longer washout due to depot effect
- Topical formulations: Shorter washout period acceptable (steady-state achieved within 1 week 4)
- Testosterone pellets: May require 3-6 months for complete clearance
Monitoring Before Surgery
Check baseline hematocrit before proceeding with surgery:
- If hematocrit >50%, delay surgery until <50% 3, 4
- This is already a relative contraindication to testosterone therapy per guidelines
When to Resume
- Wait until wound healing is complete (typically 6-12 weeks post-TKA)
- Confirm no signs of infection before restarting
- Consider switching from IM to topical formulation to reduce future surgical risk 2
Important Caveats
Balancing Hypogonadism Symptoms
While one older study 5 suggested preoperative supraphysiological testosterone might improve functional recovery, this was:
- A small pilot study (n=25)
- Published in 2002, before current infection risk data
- Contradicted by multiple recent large-scale studies showing increased complications 1, 2, 6
The mortality, morbidity, and quality of life risks from infection and reoperation far outweigh any theoretical functional benefits.
Patient Counseling
Inform patients that:
- Temporary discontinuation is for surgical safety
- Hypogonadism symptoms may temporarily worsen but are manageable
- Therapy can be resumed after successful healing
- The alternative is 2-5x higher risk of reoperation requiring additional surgery, antibiotics, and prolonged recovery
Documentation
Document in the medical record:
- Discussion of testosterone discontinuation
- Patient agreement to hold therapy
- Plan for resumption post-recovery
- Baseline testosterone and hematocrit levels
Contraindications to Holding (Rare)
The only scenario where continuing might be considered is severe symptomatic hypogonadism where discontinuation poses immediate health risks. However, elective TKA should be postponed in such cases until the patient is medically optimized, rather than proceeding with active testosterone therapy.
The evidence is clear: testosterone increases surgical complications in TKA, and temporary discontinuation is the prudent approach to minimize preventable morbidity 1, 2.